Crown Aesthetics, a division of Crown Laboratories, Inc., will expand further into Asia Pacific, and has named Jeff Sinclair as Executive Director of Sales, Asia Pacific Region, to lead the growth strategy, and a distributor network for the award winning and first FDA-cleared microneedling system, SkinPen® Precision, and its one-of-a-kind living probiotic, BIOJUVE™.
"Our expansion into the Asian market is significant," said Michael McKenna, General Manager and Executive Vice President of Crown Aesthetics. "Asia not only has a diverse population, but it is also experiencing rapid economic growth. Given the range of benefits SkinPen and BIOJUVE offer, now is a great time to bring them into this competitive market."
Sinclair, who is a new hire, brings over 25 years of sales experience to Crown. He worked for Viveve Medical, Inc., Restoration Robotics, Obagi Medical Products, Iridex, Laserscope, and Lumenis, and has built a diverse sales team that supported plastic surgery, dermatology, and general Aesthetic health care practices. Throughout his career, he has managed sales (direct and indirect), marketing, clinical training, distribution, and contract negotiations. He has a proven track record of delivering on goals and generating significant revenue growth for his companies.
"It is with great pleasure that we welcome Jeff to our international team," said Andy Moulton, Vice President, International Sales of Crown Aesthetics. "From 5 countries only four years ago to now over 45 countries, Crown Aesthetics is a welcomed and successful international organisation that truly enriches the lives it touches. I look forward to the impact Mr. Sinclair and Crown Aesthetics products have on the skin health of patients worldwide."
"I am excited to join an organisation that is committed to skin science for life," said Sinclair. "Crown's commitment to customer service, innovation, and education makes Crown a great fit for me. I look forward to leveraging my experience and bringing tremendous value to our customers in the APAC region."